Ascendis Pharma ADR
(ASND)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 814,757 | 393,496 | 288,669 | 53,917 | 9,202 |
| Cost of Goods | 107,387 | 47,892 | 48,049 | 12,788 | 4,168 |
| Gross Profit | 707,371 | 345,604 | 240,620 | 41,129 | 5,034 |
| Operating Expenses | 861,934 | 648,145 | 733,701 | 633,844 | 539,717 |
| Operating Income | -154,177 | -301,649 | -493,032 | -591,927 | -534,515 |
| Interest Expense | 233,846 | 108,239 | 47,692 | 53,193 | 4,627 |
| Other Income | 147,429 | 6,005 | 27,558 | 36,332 | 84,898 |
| Pre-tax Income | -240,593 | -403,884 | -513,166 | -608,788 | -454,244 |
| Income Tax | 17,404 | 5,241 | 7,904 | 5,665 | -434 |
| Net Income Continuous | -257,998 | -409,125 | -521,070 | -614,453 | -453,810 |
| Net Income | $-257,998 | $-409,125 | $-521,070 | $-614,453 | $-453,810 |
| EPS Basic Total Ops | -4.25 | -7.07 | -9.25 | -10.96 | -8.28 |
| EPS Basic Continuous Ops | -4.26 | -7.07 | -9.26 | -10.96 | -8.29 |
| EPS Diluted Total Ops | -4.25 | -7.07 | -9.25 | -10.96 | -8.28 |
| EPS Diluted Continuous Ops | -4.26 | -7.07 | -9.26 | -10.96 | -8.29 |
| EPS Diluted Before Non-Recurring Items | N/A | -7.07 | -9.24 | -10.96 | -8.28 |
| EBITDA(a) | $-134,156 | $-282,481 | $-472,565 | $-573,007 | $-516,306 |